Acquired Growth WillowWood has recently transitioned ownership with a majority stake acquired by CVC Catalyst III in 2026, indicating potential shifts in strategic priorities, funding flexibility, and expansion initiatives that can open doors for partnerships, OEM collaborations, and new distribution channels.

Global Leader As a global prosthetic solutions provider with awards for innovation and evidence-based research, WillowWood shows strong market credibility and a track record of product development that can be leveraged to upsell advanced components, diagnostics, and integrated service offerings to clinics and distributors.

Product Expansion Recent acquisitions and product milestones, including Xtremity and META Shock X, suggest an ongoing portfolio expansion into socket technologies and high-activity prosthetics, presenting cross-sell opportunities for compatible systems, accessories, and personalized fitting services.

Awards & Research Recognition for clinical evidence and industry innovation signals a focus on outcomes data; this creates a path for selling data analytics, outcome tracking solutions, training programs, and enhanced patient engagement tools to healthcare partners.

Mid-Mized Footprint With a revenue range of 25 to 50 million and a mid-sized employee base, WillowWood balances scale with agility, making it a prime target for scalable cloud, ERP, and CRM integrations, as well as service partnerships with mid-market distributors and clinics looking for reliable, efficient supply and support.